X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5268) 5268
Publication (427) 427
Newsletter (332) 332
Book Review (58) 58
Book Chapter (13) 13
Conference Proceeding (4) 4
Dissertation (3) 3
Transcript (2) 2
Data Set (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3937) 3937
carboplatin (3427) 3427
oncology (2945) 2945
female (2665) 2665
index medicus (2126) 2126
chemotherapy (2033) 2033
male (1755) 1755
middle aged (1691) 1691
pharmacology & pharmacy (1605) 1605
cisplatin (1581) 1581
cancer (1555) 1555
carboplatin - administration & dosage (1462) 1462
aged (1460) 1460
antineoplastic combined chemotherapy protocols - therapeutic use (1435) 1435
adult (1384) 1384
animals (1041) 1041
paclitaxel (1019) 1019
lung neoplasms - drug therapy (1000) 1000
antineoplastic agents - pharmacology (917) 917
carboplatin - pharmacology (900) 900
treatment outcome (785) 785
antineoplastic combined chemotherapy protocols - adverse effects (775) 775
carcinoma, non-small-cell lung - drug therapy (759) 759
ovarian neoplasms - drug therapy (717) 717
antineoplastic agents - therapeutic use (668) 668
paclitaxel - administration & dosage (614) 614
cell line, tumor (609) 609
mice (573) 573
research (559) 559
care and treatment (554) 554
carboplatin - adverse effects (545) 545
dose-response relationship, drug (544) 544
cisplatin - pharmacology (542) 542
ovarian cancer (512) 512
carboplatin - therapeutic use (505) 505
cisplatin - administration & dosage (505) 505
carcinoma (494) 494
antineoplastic agents - administration & dosage (492) 492
medicine & public health (489) 489
lung neoplasms - pathology (487) 487
trial (470) 470
pharmacology/toxicology (466) 466
aged, 80 and over (448) 448
drug administration schedule (447) 447
antineoplastic agents (432) 432
lung cancer (421) 421
toxicity (404) 404
combination (403) 403
disease-free survival (403) 403
neoplasm staging (403) 403
pharmacokinetics (401) 401
antimitotic agents (396) 396
therapy (394) 394
tumors (387) 387
apoptosis (382) 382
platinum (380) 380
survival (376) 376
analysis (374) 374
lung cancer, non-small cell (370) 370
antineoplastic agents - adverse effects (369) 369
carcinoma, non-small-cell lung - pathology (367) 367
antineoplastic combined chemotherapy protocols - administration & dosage (365) 365
gemcitabine (362) 362
neoplasms - drug therapy (362) 362
combined modality therapy (340) 340
survival analysis (339) 339
carboplatin - pharmacokinetics (336) 336
ovarian neoplasms - pathology (325) 325
prognosis (319) 319
survival rate (318) 318
drug therapy (316) 316
etoposide - administration & dosage (312) 312
etoposide (310) 310
cancer research (308) 308
antineoplastic agents - pharmacokinetics (305) 305
expression (300) 300
bevacizumab (298) 298
drug resistance, neoplasm (298) 298
cell survival - drug effects (297) 297
phase-ii (296) 296
deoxycytidine - analogs & derivatives (290) 290
time factors (284) 284
antineoplastic combined chemotherapy protocols - pharmacology (283) 283
organoplatinum compounds - pharmacology (279) 279
cell lung-cancer (277) 277
cancer therapies (276) 276
apoptosis - drug effects (275) 275
pharmacology (275) 275
metastasis (267) 267
immunotherapy (266) 266
docetaxel (261) 261
tumor cells, cultured (255) 255
adolescent (253) 253
cisplatin - therapeutic use (249) 249
drugs (249) 249
drug synergism (247) 247
cyclophosphamide (240) 240
retrospective studies (240) 240
rats (235) 235
patients (233) 233
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5483) 5483
Japanese (45) 45
Chinese (29) 29
French (19) 19
Spanish (12) 12
German (11) 11
Russian (7) 7
Dutch (3) 3
Polish (3) 3
Czech (2) 2
Italian (2) 2
Hebrew (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 10/2008, Volume 14, Issue 20, pp. 6456 - 6468
Purpose: It was the aim of our study to establish an extensive panel of non-small cell lung cancer (NSCLC) xenograft models useful for the testing of novel... 
xenograft | NSCLC | erlotinib | mutational analysis | anti-EGFR therapy | cetuximab | biomarker | TARGETED THERAPY | KRAS MUTATIONS | GROWTH-FACTOR RECEPTOR | NUDE-MICE | TUMOR XENOGRAFTS | GEFITINIB | ONCOLOGY | GENE-EXPRESSION | TYROSINE KINASE INHIBITOR | EGFR MUTATIONS | ANTITUMOR-ACTIVITY | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Oligonucleotide Array Sequence Analysis | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Middle Aged | Drug Resistance, Neoplasm | Immunoblotting | Male | Gene Expression Profiling | Adenocarcinoma - metabolism | Biomarkers, Tumor - metabolism | Cetuximab | Disease Models, Animal | Genes, ras - genetics | Antibodies, Monoclonal - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Etoposide - pharmacology | Mutation - genetics | Adenocarcinoma - drug therapy | Small Cell Lung Carcinoma - pathology | Carcinoma, Squamous Cell - drug therapy | Mice, Nude | Mice, Inbred NOD | Biomarkers, Tumor - genetics | Mice | Carboplatin - pharmacology | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives | Erlotinib Hydrochloride | Paclitaxel - pharmacology | Prognosis | Carcinoma, Squamous Cell - metabolism | Deoxycytidine - pharmacology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Tumor Suppressor Protein p53 - genetics | Small Cell Lung Carcinoma - metabolism | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Vinblastine - analogs & derivatives | Polymerase Chain Reaction | Adult | Female | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Large Cell - metabolism | Radiation-Sensitizing Agents - pharmacology | Tumor Suppressor Protein p53 - metabolism | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Protein Kinase Inhibitors - pharmacology | Vinblastine - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents, Phytogenic - pharmacology
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2004, Volume 96, Issue 10, pp. 739 - 749
Background. Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers... 
TUMOR-CELL LINES | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | IN-VITRO | PACLITAXEL TAXOL(R) | ONCOLOGY | 1ST-LINE CHEMOTHERAPY | RANDOMIZED-TRIAL | MONOCLONAL-ANTIBODY | CLINICAL PHARMACOKINETICS | DOCETAXEL TAXOTERE(R) | Up-Regulation | Cyclophosphamide - analogs & derivatives | Paclitaxel - pharmacology | Taxoids - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Receptor, ErbB-2 - metabolism | Deoxycytidine - pharmacology | Transplantation, Heterologous | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Female | Gene Expression Regulation, Neoplastic - drug effects | Receptor, ErbB-2 - drug effects | Disease Models, Animal | Floxuridine - pharmacology | Cell Survival - drug effects | Tumor Stem Cell Assay | Proto-Oncogene Proteins - drug effects | Enzyme-Linked Immunosorbent Assay | Antibodies, Monoclonal - pharmacology | Docetaxel | Breast Neoplasms - drug therapy | DNA, Neoplasm - drug effects | Guanine Nucleotide Exchange Factors | Drug Synergism | Animals | Mice, Nude | Cyclophosphamide - pharmacology | Cell Line, Tumor | Mice | Vinblastine - pharmacology | Carboplatin - pharmacology | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Trastuzumab | Vinorelbine | Epirubicin - pharmacology | Chemotherapy | Care and treatment | Breast cancer | Research | Health aspects
Journal Article
Future Medicinal Chemistry, ISSN 1756-8919, 01/2019, Volume 11, Issue 2, pp. 119 - 135
Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including... 
chemoresistance | cancer | cisplatin | metal-based anticancer agents | chemotherapy | CANCER-CELLS | ORGANOMETALLIC COMPOUNDS | COPPER-COMPLEXES | CHEMISTRY, MEDICINAL | PHOTODYNAMIC THERAPY | MOLECULAR-STRUCTURE | RHENIUM COMPLEXES | PROSTATE-CANCER | NITRIC-OXIDE | VITRO ANTICANCER ACTIVITY | IV COMPLEX | Rhodium - pharmacology | Iridium - pharmacology | Carboplatin - chemistry | Humans | Antineoplastic Agents - therapeutic use | Metals - therapeutic use | Ruthenium - chemistry | Ruthenium - therapeutic use | Cisplatin - chemistry | Copper - chemistry | Carboplatin - therapeutic use | Metals - chemistry | Iridium - therapeutic use | Organometallic Compounds - therapeutic use | Antineoplastic Agents - pharmacology | Iron - pharmacology | Iridium - chemistry | Rhenium - pharmacology | Gold - chemistry | Iron - chemistry | Copper - pharmacology | Cisplatin - pharmacology | Gold - pharmacology | Antineoplastic Agents - chemistry | Drug Discovery | Rhodium - therapeutic use | Ruthenium - pharmacology | Neoplasms - drug therapy | Animals | Cisplatin - therapeutic use | Iron - therapeutic use | Copper - therapeutic use | Gold - therapeutic use | Organometallic Compounds - chemistry | Rhenium - chemistry | Rhenium - therapeutic use | Carboplatin - pharmacology | Organometallic Compounds - pharmacology | Rhodium - chemistry | Metals - pharmacology
Journal Article
British Journal of Cancer, ISSN 0007-0920, 05/2002, Volume 86, Issue 10, pp. 1652 - 1657
Ruthenium complexes offer the potential of reduced toxicity, a novel mechanism of action, non-cross resistance and a different spectrum of activity compared to... 
Ovarian xenografts | Ruthenium(II) | Structure activity relationships | Drug resistance | Organometallic arene complexes | HUMAN TUMOR XENOGRAFTS | MRP1 | PROTEIN | organometallic arene complexes | ruthenium(II) | PLATINUM | TOPOISOMERASE-I | DRUG-RESISTANCE | COLORECTAL-CARCINOMA | P-GLYCOPROTEIN | ONCOLOGY | ovarian xenografts | DNA | drug resistance | ACCUMULATION | structure activity relationships | Drug Resistance, Multiple | Humans | Ovarian Neoplasms - pathology | Decitabine | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Structure-Activity Relationship | Neoplasm Proteins - metabolism | Drug Design | Edetic Acid - pharmacology | Organometallic Compounds - therapeutic use | Antimetabolites, Antineoplastic - pharmacology | Female | Antineoplastic Agents - pharmacology | Ruthenium Compounds - therapeutic use | Ovarian Neoplasms - drug therapy | Azacitidine - analogs & derivatives | Cisplatin - pharmacology | Antineoplastic Agents - chemistry | Calcium Channel Blockers - pharmacology | Ruthenium Compounds - chemistry | Verapamil - pharmacology | Xenograft Model Antitumor Assays | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Azacitidine - pharmacology | Animals | Mice, Nude | Ligands | Organometallic Compounds - chemistry | Mice | Carboplatin - pharmacology | Organometallic Compounds - pharmacology | Drug Screening Assays, Antitumor | Ruthenium Compounds - pharmacology | Experimental Therapeutics
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2019, Volume 144, Issue 4, pp. 755 - 766
Bromodomain and Extra‐Terminal (BET) proteins are historically involved in regulating gene expression and BRD4 was recently found to be involved in DNA damage... 
triple negative breast neoplasms | homologous recombination | BRCAness | synthetic lethality | BET inhibitors | BREAST-CANCER | TARGET | OLAPARIB | CARBOPLATIN | ONCOLOGY | PARP INHIBITORS | DEFICIENCY | Humans | RNA Interference | BRCA1 Protein - metabolism | Triple Negative Breast Neoplasms - pathology | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Nuclear Proteins - genetics | Recombinational DNA Repair - drug effects | Rad51 Recombinase - metabolism | Benzodiazepines - pharmacology | Rad51 Recombinase - genetics | Recombinational DNA Repair - genetics | Nuclear Proteins - metabolism | Transcription Factors - antagonists & inhibitors | Cisplatin - pharmacology | Transcription Factors - genetics | Piperazines - pharmacology | Azepines - pharmacology | Transcription Factors - metabolism | Triazoles - pharmacology | BRCA1 Protein - genetics | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Triple Negative Breast Neoplasms - genetics | Triple Negative Breast Neoplasms - metabolism | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | DNA Damage | Salts | Chromatin | Immunoprecipitation | DNA damage | Homologous recombination | Clinical trials | Homology | Lethality | DNA repair | Subgroups | Proteins | Historical account | Platinum | Inhibition | Repair | Deoxyribonucleic acid--DNA | Medical research | Phenotypes | Damage assessment | BRCA1 protein | RNA-mediated interference | Poly(ADP-ribose) polymerase | Breast cancer | Pharmacology | Gene expression | Inhibitors | Ribonucleic acids | Cell death | Cancer
Journal Article
Retina, ISSN 0275-004X, 2017, Volume 37, Issue 1, pp. 1 - 10
Journal Article
Molecules, ISSN 0022-2275, 03/2017, Volume 22, Issue 3, pp. 529 - 542
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 03/2012, Volume 104, Issue 6, pp. 476 - 487
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2014, Volume 20, Issue 8, pp. 2104 - 2114
Purpose: When evaluated in patients with ovarian and other cancer, vintafolide (EC145), a potent folate-targeted vinca alkaloid conjugate, displayed a toxicity... 
OVEREXPRESSION | ONCOLOGY | FOLATE RECEPTOR EXPRESSION | PHASE-II | CONJUGATE | TISSUES | INHIBITORS | ANTITUMOR-ACTIVITY | CELL-LINES | CANCER | EPITHELIAL OVARIAN-CARCINOMA | Folic Acid - pharmacology | Paclitaxel - pharmacology | Taxoids - pharmacology | Humans | Antineoplastic Agents - administration & dosage | Folic Acid - administration & dosage | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Neoplasms, Experimental - pathology | Vinca Alkaloids - administration & dosage | Vinca Alkaloids - pharmacology | Camptothecin - administration & dosage | Mice, Inbred DBA | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Camptothecin - analogs & derivatives | Doxorubicin - administration & dosage | Folic Acid - analogs & derivatives | Topotecan - pharmacology | Carboplatin - administration & dosage | Treatment Outcome | Cisplatin - pharmacology | Neoplasms - drug therapy | Drug Synergism | Xenograft Model Antitumor Assays | Taxoids - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Cell Line, Tumor | Topotecan - administration & dosage | Cell Proliferation - drug effects | Mice, Inbred BALB C | HeLa Cells | Carboplatin - pharmacology | Neoplasms - pathology | Camptothecin - pharmacology | Neoplasms, Experimental - drug therapy | Doxorubicin - pharmacology
Journal Article
Cell Reports, ISSN 2211-1247, 05/2017, Volume 19, Issue 8, pp. 1669 - 1684
Although non-small cell lung cancer (NSCLC) patients benefit from standard taxane-platin chemotherapy, many relapse, developing drug resistance. We established... 
lung cancer | histone methylation | taxane-platin chemotherapy | JIB-04 | GSK-J4 | KDM | histone demethylases | demethylase inhibitors | Jumonji demethylases | drug resistance | CELLS | MELANOMA | THERAPY | CHEMOTHERAPY REGIMENS | MECHANISM | GENE-EXPRESSION | LEUKEMIA | MULTIDRUG-RESISTANCE | CELL BIOLOGY | Lung Neoplasms - drug therapy | Transcription, Genetic - drug effects | Taxoids - pharmacology | Benzazepines - adverse effects | Humans | Aminopyridines - adverse effects | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Taxoids - therapeutic use | Hydrazones - adverse effects | Aminopyridines - therapeutic use | Carboplatin - therapeutic use | Hydrazones - therapeutic use | Jumonji Domain-Containing Histone Demethylases - antagonists & inhibitors | Bridged-Ring Compounds - pharmacology | Neoadjuvant Therapy | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Bridged-Ring Compounds - therapeutic use | Carcinoma, Non-Small-Cell Lung - genetics | Enzyme Inhibitors - pharmacology | Benzazepines - pharmacology | Pyrimidines - pharmacology | Enzyme Inhibitors - therapeutic use | Hydrazones - pharmacology | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Animals | Benzazepines - therapeutic use | Pyrimidines - therapeutic use | Aminopyridines - pharmacology | Pyrimidines - adverse effects | Cell Line, Tumor | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Histones - metabolism | Carboplatin - pharmacology | Methylation | Jumonji Domain-Containing Histone Demethylases - metabolism | Drug Resistance, Neoplasm - drug effects
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4769 - 4777
In patients with metastatic colorectal cancer, the predictive value of KRAS mutational status in the selection of patients for treatment with anti-epidermal... 
PHASE-III TRIAL | K-RAS MUTATIONS | RESECTED STAGE-I | SOUTHWEST-ONCOLOGY-GROUP | PROTEIN-KINASE CASCADE | EPITHELIAL-CELLS | ONCOLOGY | COLORECTAL-CANCER | EML4-ALK FUSION GENE | BRONCHIOLOALVEOLAR-CARCINOMA | GENE COPY NUMBER | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Predictive Value of Tests | Receptor, Epidermal Growth Factor - genetics | Translocation, Genetic | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Paclitaxel - pharmacology | Microtubule-Associated Proteins - genetics | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | ras Proteins - metabolism | Deoxycytidine - pharmacology | Antineoplastic Agents - therapeutic use | Patient Selection | Antibodies, Monoclonal, Humanized | Protein-Tyrosine Kinases - genetics | Receptor, Epidermal Growth Factor - metabolism | Serine Endopeptidases - genetics | Biomarkers, Tumor - metabolism | Cell Cycle Proteins - genetics | Antineoplastic Agents - pharmacology | Cetuximab | Precision Medicine | Lung Neoplasms - genetics | Proto-Oncogene Proteins - metabolism | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Antibodies, Monoclonal - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Proto-Oncogene Proteins - genetics | Clinical Trials as Topic | Cisplatin - pharmacology | Carcinoma, Non-Small-Cell Lung - mortality | Receptor Protein-Tyrosine Kinases | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Carboplatin - pharmacology | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives
Journal Article